A process for the preparation of (‐)‐englerin A and intermediates thereof.
What we offer:
(‐)‐Englerin A, extracted from the plant Phyllanthus engleri, was
recently shown to have a strong activity in inhibiting the growth of renal
cancer cells. (‐)‐Englerin A and its analogs might enable to tackle with the
disadvantages of current therapies, thanks to the high activity and selectivity
of the natural product against renal cancer cells. The total synthesis
developped in our institute allows for the preparation of (‐)‐Englerin A in 18
steps, with an overall yield of 7%, from geraniol. The key step of the
reaction is a gold catalyzed cyclization step that allows for the
establishment of the polycyclic scaffold of (‐)‐ Englerin A stereoselectively.
This procedure allows for the preparation and screening of
analog compounds of the natural product from key intermediates.
What are we looking for:
This technology is currently being developed and the preparation of a drug library is in course for activity screening and hit identification. We are looking for partners willing to assist this project and benefit from the IP of the technology under the form of a license:
At ICIQ, we consider that patents are safe and solid tools to provide protection
from competitors. This is why we file patents for our developed technologies: to
give our co-development projects with industry a strong starting IP position. As a research centre, our goal is always to codevelop our technology adapting it to the industrial partner’s specific needs and ultimately transfer the technology to this company, with a flexible licensing strategy adapted to each case.
- ] Organic substances
- ] Pharmaceutics
- Licence Agreement
- Research and development
- Technical Co-operation